Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.55 |
| ▸ | GRN | P28799 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600591 | 0.85 | GRN (0.62) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL1600233 | 0.81 | GRN (0.80) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL15948863 | 0.81 | GRN (0.61) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL15946936 | 0.80 | GRN (0.60) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL1600416 | 0.80 | CDK8 (0.64) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL1517048 | 0.78 | ALDH1A1 (0.59) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL13263169 | 0.78 | GRN (0.57) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL19669089 | 0.78 | GRN (0.57) | CDK8GRNSORT1MAPK14MAPK13 | |
| SCHEMBL12705325 | 0.74 | GRN (0.78) | GRNSORT1MAPK14MAPK13MAPK12 | |
| SCHEMBL1600309 | 0.74 | CDK8 (0.82) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670787-B1 | CYTOKINE INHIBITORS | ITHERX PHARMA INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1670787-A4 | CYTOKINE INHIBITORS | KEMIA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1670787-A2 | CYTOKINE INHIBITORS | Kemia, INC. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005023761-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | CDK8 2319/4885GRN 3147/4885SORT1 1605/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CDK8 2319/4885GRN 3147/4885SORT1 1605/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | CDK8 988/4885GRN 4668/4885SORT1 4163/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CDK8 2319/4885GRN 3147/4885SORT1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.